226 related articles for article (PubMed ID: 32741743)
1. Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy in Patients With Acute Myeloid Leukemia Relapsing After Allogenic Stem Cell Transplantation.
Genthon A; Brissot E; Malard F; van de Wyngaert Z; Bonnin A; Banet A; Marjanovic Z; Ikhlef S; Lapusan S; Sestili S; Corre E; Paviglianiti A; Adaeva R; 'Hammedi-Bouzina FM; Labopin M; Dulery R; Mohty M; Legrand O
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):791-796. PubMed ID: 32741743
[TBL] [Abstract][Full Text] [Related]
2. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.
Jen EY; Ko CW; Lee JE; Del Valle PL; Aydanian A; Jewell C; Norsworthy KJ; Przepiorka D; Nie L; Liu J; Sheth CM; Shapiro M; Farrell AT; Pazdur R
Clin Cancer Res; 2018 Jul; 24(14):3242-3246. PubMed ID: 29476018
[TBL] [Abstract][Full Text] [Related]
3. Gemtuzumab ozogamicin monotherapy prior to stem cell infusion induces sustained remission in a relapsed acute myeloid leukemia patient after allogeneic stem cell transplantation: A case report.
Sumiyoshi R; Tashiro H; Saito S; Matsuo T; Yamamoto T; Matsumoto K; Ooi J; Shirafuji N
Medicine (Baltimore); 2020 Aug; 99(35):e22064. PubMed ID: 32871966
[TBL] [Abstract][Full Text] [Related]
4. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.
Pilorge S; Rigaudeau S; Rabian F; Sarkozy C; Taksin AL; Farhat H; Merabet F; Ghez S; Raggueneau V; Terré C; Garcia I; Renneville A; Preudhomme C; Castaigne S; Rousselot P
Am J Hematol; 2014 Apr; 89(4):399-403. PubMed ID: 24375467
[TBL] [Abstract][Full Text] [Related]
5. Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children-the Polish Pediatric Leukemia and Lymphoma Study Group experience.
Pawinska-Wasikowska K; Czogala M; Skoczen S; Surman M; Rygielska M; Ksiazek T; Pac A; Wieczorek A; Skalska-Sadowska J; Samborska M; Wachowiak J; Chaber R; Tomaszewska R; Szczepanski T; Zielezinska K; Urasinski T; Moj-Hackemer M; Kalwak K; Kozlowska M; Irga-Jaworska N; Balwierz W; Bukowska-Strakova K
Front Immunol; 2023; 14():1268993. PubMed ID: 38187390
[TBL] [Abstract][Full Text] [Related]
6. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
Pollard JA; Guest E; Alonzo TA; Gerbing RB; Loken MR; Brodersen LE; Kolb EA; Aplenc R; Meshinchi S; Raimondi SC; Hirsch B; Gamis AS
J Clin Oncol; 2021 Oct; 39(28):3149-3160. PubMed ID: 34048275
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of gemtuzumab ozogamicin for relapsed acute myeloid leukemia: single-institution experience.
Hosono N; Ookura M; Araie H; Morita M; Itoh K; Matsuda Y; Yamauchi T
Int J Hematol; 2021 Mar; 113(3):362-369. PubMed ID: 33219461
[TBL] [Abstract][Full Text] [Related]
8. Association of fludarabin, cytarabine, and fractioned gemtuzumab followed by hematopoietic stem cell transplantation for first-line refractory acute myeloid leukemia in children: A single-center experience.
Penel-Page M; Plesa A; Girard S; Marceau-Renaut A; Renard C; Bertrand Y
Pediatr Blood Cancer; 2020 Jun; 67(6):e28305. PubMed ID: 32307866
[TBL] [Abstract][Full Text] [Related]
9. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
10. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
[TBL] [Abstract][Full Text] [Related]
11. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
[TBL] [Abstract][Full Text] [Related]
12. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials.
Li X; Xu SN; Qin DB; Tan Y; Gong Q; Chen JP
Ann Oncol; 2014 Feb; 25(2):455-61. PubMed ID: 24478322
[TBL] [Abstract][Full Text] [Related]
13. Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis.
Xu Q; He S; Yu L
Front Immunol; 2021; 12():683595. PubMed ID: 34484181
[TBL] [Abstract][Full Text] [Related]
14. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
[TBL] [Abstract][Full Text] [Related]
15. Gemtuzumab Ozogamicin in
Schlenk RF; Paschka P; Krzykalla J; Weber D; Kapp-Schwoerer S; Gaidzik VI; Leis C; Fiedler W; Kindler T; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Horst HA; Koller E; Wulf G; Schleicher J; Bentz M; Greil R; Hertenstein B; Krauter J; Martens U; Nachbaur D; Abu Samra M; Girschikofsky M; Basara N; Benner A; Thol F; Heuser M; Ganser A; Döhner K; Döhner H
J Clin Oncol; 2020 Feb; 38(6):623-632. PubMed ID: 31851556
[TBL] [Abstract][Full Text] [Related]
16. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
Stadtmauer EA
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
[TBL] [Abstract][Full Text] [Related]
17. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
[TBL] [Abstract][Full Text] [Related]
18. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
19. Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia.
Chantepie SP; Reboursiere E; Mear JB; Gac AC; Salaun V; Benabed K; Cheze S; Johnsonansah H; Macro M; Vilque JP; Reman O
Leuk Lymphoma; 2015; 56(8):2326-30. PubMed ID: 25393676
[TBL] [Abstract][Full Text] [Related]
20. Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation.
Koren-Michowitz M; Maayan H; Apel A; Shem-Tov N; Yerushalmi R; Volchek Y; Avigdor A; Shimoni A; Nagler A
Ann Hematol; 2015 Mar; 94(3):375-8. PubMed ID: 25307457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]